Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Lexibulin

Lexibulin
Contact us for more batch information
Select Batch
Purity:99.22%
Resource Download

Lexibulin

Catalog No. T2090Cas No. 917111-44-5
Lexibulin (CYT-997)(CYT-997) is a potent tubulin polymerization inhibitor (IC50: 10-100 nM, in Y cell lines). Lexibulin blocks the formation of the mitotic spindle and leading to cell cycle arrest at the G2/M phase; this may result in disruption of the tumor vasculature and tumor blood flow, and tumor cell death.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$43In Stock
5 mg$97In Stock
10 mg$183In Stock
25 mg$368In Stock
50 mg$566In Stock
100 mg$813In Stock
1 mL x 10 mM (in DMSO)$112In Stock
Bulk & Custom
Add to Cart

Related Compound Libraries of "Lexibulin"

Product Introduction

Bioactivity
Description
Lexibulin (CYT-997)(CYT-997) is a potent tubulin polymerization inhibitor (IC50: 10-100 nM, in Y cell lines). Lexibulin blocks the formation of the mitotic spindle and leading to cell cycle arrest at the G2/M phase; this may result in disruption of the tumor vasculature and tumor blood flow, and tumor cell death.
In vitro
CYT997 (7.5 mg/kg, i.p.) administration to liver metastasis significantly reduced blood flow at 6 hours, with an effect similar to the positive control CA4P (100 mg/kg). Consistent with its in vitro anti-myeloma activity, treatment with CYT997 (15 mg/kg/day) in an aggressive systemic myeloid leukemia mouse model extended lifespan. Compared to its intravenous half-life (1.5 hours), the half-life of CYT997 when administered orally to rats was slightly longer (2.5 hours), with an absolute oral bioavailability of 50%-70%. In PC3 xenograft mice, oral administration of CYT997 showed a stronger inhibitory effect on tumor growth than Paclitaxel, and this effect was dose-dependent. CYT997 was also effective in a syngeneic model carrying mouse breast cancer 4T1 cells, which exhibits certain resistance to Paclitaxel treatment.
In vivo
CYT997 exhibits toxicity across 16 cancer cell lines (IC50: 9/101 nM in HepG2 and KHOS/NP cells) and shows notably higher efficacy in HCT15 cells, which possess the multi-drug resistance mechanism Pgp (MDR+) (IC50: 52 nM). When treating A549 cells for 24 hours, CYT997 (1 μM) induces rapid reorganization of microtubules, including disruption of the existing microtubule network and accumulation of cytoplasmic microtubule proteins at the foci, significantly altering cell morphology. This entails a loss of adhesion in cells and a reduction in cell number. By inhibiting microtubule polymerization, CYT997 arrests the cell cycle at the G2-M phase boundary, leads to an increase in phosphorylated Bcl-2, and elevates the expression of cyclin B1, activation of caspase-3, and production of PARP. Treatment with CYT997 for one hour considerably enhances the permeability of HUVEC monolayers (IC50: 80 nM) in a rapid and reversible manner. Consistent with the disruption of cellular microtubule proteins, CYT997 effectively halts proliferation, induces cell cycle arrest, and triggers apoptosis in human bone marrow cell lines and primary MM cells.
Kinase Assay
Turbidimetric assay for tubulin polymerization: The effect of CYT997 on microtubule polymerization is determined using conventional turbidimetric assay using bovine neuronal tubulin in which the assembly of microtubules is monitored by an increase in absorbance at 340 nm. Increasing concentrations of CYT997 is added to 100 μL of tubulin/GTP/glycerol. Turbidimetric assays of microtubule assembly is done by incubating bovine microtubule protein in cuvettes at 37 °C in a thermostatically controlled spectrophotometer measuring the change in absorbance at 340 nm over time in PEM buffer [80 nM PIPES (pH 6.9), 2 mM MgCl2, 0.5 mM EGTA, and 5% glycerol].
Cell Research
Cells are exposed to various concentrations of CYT997 for ~72 hours. Cell proliferation is assessed with either the Alamar blue or MTT assays. For MTT assays, 5 mg/mL of MTT is added to all wells, plates are incubated for 6 hours at 37 °C, and then lysis buffer is added (10% SDS in 0.01 N HCl) and absorbance is measured at 620 nm in a BMG Technologies Lumistar or Polarstar plate reader. For Alamar blue assays, Alamar blue (10 μL/well) is added to each well and the plates are incubated at 37 °C for 4 hours. The fluorescence is then measured using a fluorescence plate reader with an excitation filter at 544 nm and an emission filter at 590 nm. For cell cycle analysis, cells are fixed and permeabilized with 70% ethanol in PBS and incubated at 4 °C overnight. RNase-treated samples (10 μg RNase/mL for 20 minutes at 37 °C) are stained with propidium iodide (5 μg/mL) at 4 °C for a minimum of 10 minutes. Cell cycle variables are determined by fluorescence-activated cell sorting (FACS) analysis using a Beckman-Coulter Quanta SC MPL system and analyzed using CXP Software. For apoptosis analysis, cells are detached and collected. Annexin staining is done using the Vybrant Apoptosis Assay Kit. Cells are stored on ice and analyzed on a Beckman Coulter Quanta MPL within 1 hour of preparation. Annexin V–positive cells are determined using two-channel analysis.(Only for Reference)
AliasCYT-997
Chemical Properties
Molecular Weight434.53
FormulaC24H30N6O2
Cas No.917111-44-5
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
Ethanol: 16 mg/mL (36.8 mM)
DMSO: 80 mg/mL (184.1 mM)
Solution Preparation Table
DMSO/Ethanol
1mg5mg10mg50mg
1 mM2.3013 mL11.5067 mL23.0134 mL115.0669 mL
5 mM0.4603 mL2.3013 mL4.6027 mL23.0134 mL
10 mM0.2301 mL1.1507 mL2.3013 mL11.5067 mL
20 mM0.1151 mL0.5753 mL1.1507 mL5.7533 mL
DMSO
1mg5mg10mg50mg
50 mM0.0460 mL0.2301 mL0.4603 mL2.3013 mL
100 mM0.0230 mL0.1151 mL0.2301 mL1.1507 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords